As cell and gene therapies (CGTs) continue to transform treatment for serious disease, a critical challenge has emerged: geography.
Today, the vast majority of CGT treatment is concentrated at large academic medical centers in major metropolitan areas. Yet millions of people in rural America reside in “CGT deserts” without easy access to these advanced therapies.
McKesson has developed an interactive map of Qualified Treatment Centers (QTCs) in 109 metropolitan regions across the US as a resource for the industry to illustrate where CGT care is available today – and where the opportunities for future growth exist.
Data Sources:
All data sourced by Health Market Experts LLC as of July 2024. Sources included the American Society of Gene and Cell Therapy (ASGCT), the Foundation for the Accreditation of Cellular Therapy (FACT), BMT Infonet, and product websites of numerous cell and gene therapies.
Methodology:
We organized the list of qualified treatment centers by city, state and ZIP code, and then segmented the list using Designated Market Area (DMA) data, which defines distinct markets or metropolitan regions across the US using ZIP codes.